STAG1 and hyperamylasemia: The absence of serum hyperamylasemia (< 100 U/L) was associated with a 2.2% risk of developing POPF, compared to 38.2% in patients with SA-1 > 100 U/L (PPV = 38.2%, NPV = 97.8%).